chr2-232747740-A-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_001103146.3(GIGYF2):āc.167A>Gā(p.Asn56Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000384 in 1,613,654 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00031 ( 0 hom., cov: 32)
Exomes š: 0.00039 ( 0 hom. )
Consequence
GIGYF2
NM_001103146.3 missense
NM_001103146.3 missense
Scores
1
4
13
Clinical Significance
Conservation
PhyloP100: 7.49
Genes affected
GIGYF2 (HGNC:11960): (GRB10 interacting GYF protein 2) This gene contains CAG trinucleotide repeats and encodes a protein containing several stretches of polyglutamine residues. The encoded protein may be involved in the regulation of tyrosine kinase receptor signaling. This gene is located in a chromosomal region that was genetically linked to Parkinson disease type 11, and mutations in this gene were thought to be causative for this disease. However, more recent studies in different populations have been unable to replicate this association. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.08886388).
BS2
High AC in GnomAd4 at 47 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GIGYF2 | NM_001103146.3 | c.167A>G | p.Asn56Ser | missense_variant | 4/29 | ENST00000373563.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GIGYF2 | ENST00000373563.9 | c.167A>G | p.Asn56Ser | missense_variant | 4/29 | 1 | NM_001103146.3 | P4 |
Frequencies
GnomAD3 genomes AF: 0.000309 AC: 47AN: 152234Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
47
AN:
152234
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000263 AC: 66AN: 251020Hom.: 0 AF XY: 0.000199 AC XY: 27AN XY: 135700
GnomAD3 exomes
AF:
AC:
66
AN:
251020
Hom.:
AF XY:
AC XY:
27
AN XY:
135700
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000392 AC: 573AN: 1461302Hom.: 0 Cov.: 31 AF XY: 0.000348 AC XY: 253AN XY: 726984
GnomAD4 exome
AF:
AC:
573
AN:
1461302
Hom.:
Cov.:
31
AF XY:
AC XY:
253
AN XY:
726984
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000308 AC: 47AN: 152352Hom.: 0 Cov.: 32 AF XY: 0.000282 AC XY: 21AN XY: 74506
GnomAD4 genome
AF:
AC:
47
AN:
152352
Hom.:
Cov.:
32
AF XY:
AC XY:
21
AN XY:
74506
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
3
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
4
ExAC
AF:
AC:
39
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:2Other:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 17, 2023 | Variant summary: GIGYF2 c.167A>G (p.Asn56Ser) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00026 in 251020 control chromosomes. This frequency does not allow conclusions about variant significance. c.167A>G has been reported in the literature with conflicting reports of its association with Parkinson Disease with some studies reporting non-segregation with disease (example Nichols_2009, Vilarino-Guell_2009, Zimprich_2009), questioning the association with Parkinson Disease (example, Vilarino-Guell_2009) and some reporting it as a possible risk factor in Caucasians but not in Asians (example, Zhang_2015). These report(s) do not provide unequivocal conclusions about association of the variant with Parkinson Disease 11, Autosomal Dominant, Susceptibility To. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 19279319, 19133664, 26152800, 19250854). No submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
GIGYF2-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 29, 2024 | The GIGYF2 c.167A>G variant is predicted to result in the amino acid substitution p.Asn56Ser. This variant has been reported in individuals with Parkinson disease, although it did not segregate with disease in some families (Lautier et al. 2008. PubMed ID: 18358451; Zimprich et al. 2009. PubMed ID: 19250854; Nichols et al. 2009. PubMed ID: 19279319). It has also been observed in controls (Guella et al. 2010. PubMed ID: 20060621; Meeus et al. 2011. PubMed ID: 19321232). This variant has been described as a risk factor with an odds ratio of 1.7 (95% CI 0.98-2.90, P-value=0.06) reported in a recent publication (Zhang et al. 2015. PubMed ID: 26152800; Supplementary Table 3, Pitz et al. 2024. PubMed ID: 38191580). This variant is reported in 0.050% of alleles in individuals of European (non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Parkinson disease 11, autosomal dominant, susceptibility to Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Aug 01, 2009 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
.;T;T;.;.;.;.;T;T;.;.;T;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;.;D;.;D;D;D;D;D;D;D;D;D
M_CAP
Benign
D
MetaRNN
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationTaster
Benign
D;D;D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
.;N;D;N;D;D;D;N;N;N;N;D;N
REVEL
Benign
Sift
Benign
.;T;T;T;T;T;T;T;T;T;T;T;T
Sift4G
Uncertain
D;D;T;D;T;T;T;D;T;D;D;T;D
Polyphen
0.0010
.;B;.;.;.;.;.;B;.;.;.;.;.
Vest4
MVP
MPC
0.31
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at